Cargando…
Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases
Chinese medicine is a national treasure that has been passed down for thousands of years in China. According to the statistics of the World Health Organization, there are currently four billion people in the world who use Chinese medicine to treat diseases, accounting for 80% of the world’s total po...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987446/ https://www.ncbi.nlm.nih.gov/pubmed/32038243 http://dx.doi.org/10.3389/fphar.2019.01564 |
_version_ | 1783492142847492096 |
---|---|
author | Guo, Yong-Zhi Jiang, Ying-Nan Li, Yi-Fang Kurihara, Hiroshi Dai, Yi He, Rong-Rong |
author_facet | Guo, Yong-Zhi Jiang, Ying-Nan Li, Yi-Fang Kurihara, Hiroshi Dai, Yi He, Rong-Rong |
author_sort | Guo, Yong-Zhi |
collection | PubMed |
description | Chinese medicine is a national treasure that has been passed down for thousands of years in China. According to the statistics of the World Health Organization, there are currently four billion people in the world who use Chinese medicine to treat diseases, accounting for 80% of the world’s total population. However, the obscurity of its theory, its unmanageable quality, its complex compositions, and the unknown effective substances and mechanisms are great obstacles to the internationalization of Chinese medicine. Here, we propose a new strategy for the development of Chinese medicine: the clinical prescription (C)-protein (P)-small-molecule (S)-disease (D) strategy, namely the CPSD strategy. The strategy uses clinical prescriptions as the source of medicine and uses computer simulation technology to find small-molecule drugs targeting therapeutic proteins for treating specific diseases so as to deepen awareness of the value of Chinese medicine. At the same time, this article takes cardiovascular drug development as an example to introduce the application of CPSD, which will be instrumental in the further development, modernization, and internationalization of Chinese medicine. |
format | Online Article Text |
id | pubmed-6987446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69874462020-02-07 Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases Guo, Yong-Zhi Jiang, Ying-Nan Li, Yi-Fang Kurihara, Hiroshi Dai, Yi He, Rong-Rong Front Pharmacol Pharmacology Chinese medicine is a national treasure that has been passed down for thousands of years in China. According to the statistics of the World Health Organization, there are currently four billion people in the world who use Chinese medicine to treat diseases, accounting for 80% of the world’s total population. However, the obscurity of its theory, its unmanageable quality, its complex compositions, and the unknown effective substances and mechanisms are great obstacles to the internationalization of Chinese medicine. Here, we propose a new strategy for the development of Chinese medicine: the clinical prescription (C)-protein (P)-small-molecule (S)-disease (D) strategy, namely the CPSD strategy. The strategy uses clinical prescriptions as the source of medicine and uses computer simulation technology to find small-molecule drugs targeting therapeutic proteins for treating specific diseases so as to deepen awareness of the value of Chinese medicine. At the same time, this article takes cardiovascular drug development as an example to introduce the application of CPSD, which will be instrumental in the further development, modernization, and internationalization of Chinese medicine. Frontiers Media S.A. 2020-01-22 /pmc/articles/PMC6987446/ /pubmed/32038243 http://dx.doi.org/10.3389/fphar.2019.01564 Text en Copyright © 2020 Guo, Jiang, Li, Kurihara, Dai and He http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Guo, Yong-Zhi Jiang, Ying-Nan Li, Yi-Fang Kurihara, Hiroshi Dai, Yi He, Rong-Rong Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases |
title | Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases |
title_full | Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases |
title_fullStr | Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases |
title_full_unstemmed | Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases |
title_short | Clinical Prescription-Protein-Small Molecule-Disease Strategy (CPSD), A New Strategy for Chinese Medicine Development: A Case Study in Cardiovascular Diseases |
title_sort | clinical prescription-protein-small molecule-disease strategy (cpsd), a new strategy for chinese medicine development: a case study in cardiovascular diseases |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987446/ https://www.ncbi.nlm.nih.gov/pubmed/32038243 http://dx.doi.org/10.3389/fphar.2019.01564 |
work_keys_str_mv | AT guoyongzhi clinicalprescriptionproteinsmallmoleculediseasestrategycpsdanewstrategyforchinesemedicinedevelopmentacasestudyincardiovasculardiseases AT jiangyingnan clinicalprescriptionproteinsmallmoleculediseasestrategycpsdanewstrategyforchinesemedicinedevelopmentacasestudyincardiovasculardiseases AT liyifang clinicalprescriptionproteinsmallmoleculediseasestrategycpsdanewstrategyforchinesemedicinedevelopmentacasestudyincardiovasculardiseases AT kuriharahiroshi clinicalprescriptionproteinsmallmoleculediseasestrategycpsdanewstrategyforchinesemedicinedevelopmentacasestudyincardiovasculardiseases AT daiyi clinicalprescriptionproteinsmallmoleculediseasestrategycpsdanewstrategyforchinesemedicinedevelopmentacasestudyincardiovasculardiseases AT herongrong clinicalprescriptionproteinsmallmoleculediseasestrategycpsdanewstrategyforchinesemedicinedevelopmentacasestudyincardiovasculardiseases |